328289-85-6

Basic information

• Product Name: Methanesulfonamide, N-[2-(dimethylamino)ethyl]-N-(4-nitrophenyl)-
• CAS NO: 328289-85-6
• Molecular Formula: C11H17N3O4S
• Molecular Weight: 287.34
• Mol File: 328289-85-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Methanesulfonamide, N-[2-(dimethylamino)ethyl]-N-(4-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonamide, N-[2-(dimethylamino)ethyl]-N-(4-nitrophenyl)-(328289-85-6)
• EPA Substance Registry System: Methanesulfonamide, N-[2-(dimethylamino)ethyl]-N-(4-nitrophenyl)-(328289-85-6)

Safety Data

• Hazardous Substances Data: 328289-85-6(Hazardous Substances Data)

Upstream product

• 5825-62-7 N-(4-nitrophenyl)methanesulfonamide 
• 4535-90-4 N-methyl-2-chloroethylamine hydrochloride 
• 4584-46-7 (2-chloroethyl)dimethylamine hydrochloride 

Downstream Products

• 262368-73-0 N-(4-aminophenyl)-N-(2-(dimethylamino)ethyl)methanesulfonamide 

Relevant articles and documents

ALK5 INHIBITOR CONJUGATES AND USES THEREOF

The present disclosure relates to targeted drug conjugates comprising ALK5 inhibitors and targeting moieties that direct the ALK5 inhibitors to cells involved in fibrosis and cancer, for example myofibroblasts, activated fibroblasts and transitioning fibr

ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES

The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.

Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)

Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a newtreatment modality in oncology. Preclinical findings suggest that blockade of additional pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor receptors (FGFR and PDGFR), may improve the efficacy of pharmacological cancer treatment. Indolinones substituted in position 6 were identified as selective inhibitors of VEGF-, PDGF-, and FGF-receptor kinases. In particular, 6-methoxycarbonyl-substituted indolinones showed a highly favorable selectivity profile. Optimization identified potent inhibitors of VEGF-related endothelial cell proliferation with additional efficacy on pericyctes and smooth muscle cells. In contrast, no direct inhibition of tumor cell proliferation was observed. Compounds 2 (BIBF 1000) and 3 (BIBF 1120) are orally available and display encouraging efficacy in in vivo tumor models while being well tolerated. The triple angiokinase inhibitor 3 is currently in phase III clinical trials for the treatment of nonsmall cell lung cancer.